Mr. Huitt Tracey reports

NERVGEN ENGAGES RUSSO PARTNERS LLC TO PROVIDE PUBLIC RELATIONS SERVICES

Nervgen Pharma Corp. has engaged Russo Partners LLC, a New York based full-service strategic communications firm to provide media and public relations and related services for the company.

Russo Partners was engaged for a minimum period of three months and will continue thereafter on a month-to-month basis unless terminated by either party with 30 days of notice. It is expected that the cash compensation that is paid in the first 12 months will not exceed $200,000 (U.S.). Russo Partners has no other indirect or direct interest in the company. The appointment of Russo Partners as a public relations consultant to Nervgen is subject to regulatory acceptance of applicable filings with the TSX Venture Exchange.

About Nervgen Pharma Corp.

Nervgen is a clinical-stage biotechnology company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Nervgen's lead drug candidate, NVG-291, is currently being evaluated in a phase 1b/2a clinical trial in the company's initial target indication -- spinal cord injury.

We seek Safe Harbor.